Clinical Trials for Kidney Cancer

Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Pediatric and young adult patients (ages 1–30) with relapsed/refractory, EGFR-expressing non-CNS solid tumors receive a single infusion of autologous CAR T cells targeting the EGFR806 conformational epitope (4-1BBζ; with EGFRt suicide marker), with a second arm co-expressing an added CD19 CAR (4-1BBζ; HER2tG suicide marker) to enhance expansion/persistence. Key aims are to assess safety, dose, feasibility, and CAR persistence; lymphodepletion specifics not described.

ClinicalTrials.gov ID: NCT03618381

A Phase I Study of Vorinostat in Combination With Vincristine, Irinotecan, and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors and CNS Malignancies

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Relapsed/refractory pediatric, adolescent, and young adult patients (≤30 years) with histologically confirmed solid tumors or CNS malignancies receive vincristine/irinotecan/temozolomide (VIT), with vorinostat added from cycle 2 onward in a dose-escalation schema. Vorinostat is an oral histone deacetylase (HDAC) inhibitor intended to enhance DNA-damaging chemotherapy sensitivity; trial defines its tolerated dose with VIT and assesses preliminary activity.

ClinicalTrials.gov ID: NCT04308330

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Enrolling adults with metastatic rare genitourinary cancers across multiple histologic cohorts (e.g., small cell/neuroendocrine bladder, variant urothelial, penile, sarcomatoid/unclassified RCC, collecting duct, renal medullary, urethral; including a bone-only GU cohort), with up to two prior lines allowed (cohort-specific exceptions. Patients receive cabozantinib (MET/VEGFR2/AXL multi-kinase inhibitor) plus nivolumab (PD-1) and ipilimumab (CTLA-4) for up to 2 years.

ClinicalTrials.gov ID: NCT03866382

An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with advanced or metastatic renal cell carcinoma, urothelial carcinoma, or castration-resistant prostate cancer receive oral DCC-2812 monotherapy, a first-in-human, selective GCN2 activator that engages the integrated stress response (eIF2α phosphorylation/ATF4) to disrupt tumor survival pathways. Dose-escalation evaluates safety, dose-limiting toxicities, and PK, with preliminary antitumor activity assessed.

ClinicalTrials.gov ID: NCT06966024

Phase Ib Trial of Erdafitinib Combined With Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma With FGFR2/3 Genetic Alterations

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with locally advanced/metastatic urothelial carcinoma harboring activating FGFR2/3 alterations after progression on platinum and a PD‑1/L1 inhibitor (including cisplatin-ineligible) receive erdafitinib (oral pan-FGFR1–4 TKI) plus enfortumab vedotin (Nectin‑4–targeted MMAE ADC). Requires measurable disease and adequate organ function; excludes prior FGFR inhibitors or enfortumab/MMAE ADCs and significant ocular/cardiovascular issues.

ClinicalTrials.gov ID: NCT04963153

Phase 1/2 Study of PRO1160 in Patients With Metastatic Renal Cell Carcinoma (RCC), Metastatic or Relapsed Nasopharyngeal Carcinoma (NPC), or Advanced (Stage III or IV) Non-Hodgkin Lymphoma (NHL)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with relapsed/refractory metastatic RCC (clear cell or papillary), EBV-associated NPC, or advanced NHL (including DLBCL, FL, MCL) receive GEN1160 (PRO1160), a CD70-directed antibody–drug conjugate delivering an exatecan topoisomerase-1 inhibitor payload, given IV Day 1 of 21-day cycles; expansion focuses on DLBCL NOS after ≥2 prior regimens including CD20 chemoimmunotherapy. Excludes prior CD70 therapy/topo-1 ADCs, recent transplants/intensive therapy, active CNS disease (expansion), and significant uncontrolled comorbidities.

ClinicalTrials.gov ID: NCT05721222

A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG™) in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with locally advanced or metastatic clear cell RCC (any VHL status) receive oral HC-7366—an activator of the GCN2 integrated stress response pathway—either alone or combined with belzutifan (HIF-2α inhibitor), with combination dose escalation/expansion to define MTD/RP2D. Suitable for patients needing a belzutifan-based regimen or eligible for first- or later-line investigational therapy in ccRCC.

ClinicalTrials.gov ID: NCT06234605

A Phase 1/2a, Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with advanced, HLA‑G–positive solid tumors (ECOG 0–1) after standard therapies receive leukapheresis, fludarabine/cyclophosphamide lymphodepletion, then a single infusion of IVS‑3001, an autologous third‑generation CAR‑T targeting HLA‑G (an immune checkpoint ligand for ILT2/ILT4). Phase 2a includes cohorts for clear cell RCC post‑CPI/TKI, epithelial ovarian cancer post‑platinum (± prior PARP if BRCA1/2‑mutant), and other HLA‑G+ tumors without standard options.

ClinicalTrials.gov ID: NCT05672459

A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Severe Renal Impairment and Cancer Patients With Normal Renal Function

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with AML/MDS or other cancers lacking standard options are enrolled into cohorts with severe renal impairment (CLcr <30 mL/min, not on dialysis) or normal renal function to receive the approved fixed-dose oral decitabine/cedazuridine (35/100 mg) regimen. Decitabine is a DNA methyltransferase inhibitor (hypomethylating agent) and cedazuridine is a cytidine deaminase inhibitor that boosts decitabine bioavailability; the study compares pharmacokinetics and safety between renal function groups.

ClinicalTrials.gov ID: NCT04953897

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with metastatic/unresectable melanoma (PD‑1–refractory or PD‑1–naïve) or metastatic clear‑cell RCC refractory to PD‑1/PD‑L1–based therapy receive pembrolizumab (PD‑1 blockade) combined with high‑dose aldesleukin/IL‑2 (T‑cell activation) given inpatient. Single‑arm design aims to improve objective response; excludes significant autoimmune disease, prior severe irAEs, active infection, or major cardiopulmonary compromise.

ClinicalTrials.gov ID: NCT05155033